Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus

NCT01293461 is registered in ClinicalTrials.gov with Cebix Incorporated as lead sponsor.

NCT NCT01293461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01293461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus
Lead sponsor
Cebix Incorporated
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2011
Completion date
October 31, 2012
Enrollment
72 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, peripheral diabetic neuropathy, type 1 diabetes